Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity

Ye Li; David L. Hermanson; Branden S. Moriarity; Dan S. Kaufman

doi:10.1016/j.stem.2018.06.002

journal article Open Access Aug 01, 2018

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity

Ye Li

David L. Hermanson Branden S. Moriarity Dan S. Kaufman

Cell Stem Cell Vol. 23 No. 2 pp. 181-192.e5 · Elsevier BV

View at Publisher Save 10.1016/j.stem.2018.06.002

Topics

No keywords indexed for this article. Browse by subject →

References

75

[1]

Ahmed "Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma" J. Clin. Oncol. (2015) 10.1200/jco.2014.58.0225

[2]

Altvater "2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells" Clin. Cancer Res. (2009) 10.1158/1078-0432.ccr-08-2810

[3]

Bachanova "NK cells in therapy of cancer" Crit. Rev. Oncog. (2014) 10.1615/critrevoncog.2014011091

[4]

Bachanova "Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein" Blood (2014) 10.1182/blood-2013-10-532531

[5]

Barrett "Chimeric antigen receptor therapy for cancer" Annu. Rev. Med. (2014) 10.1146/annurev-med-060512-150254

[6]

Beatty "Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies" Cancer Immunol. Res. (2014) 10.1158/2326-6066.cir-13-0170

[7]

Bollino "Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy" Transl. Res. (2017) 10.1016/j.trsl.2017.06.003

[8]

Bryceson "Activation, coactivation, and costimulation of resting human natural killer cells" Immunol. Rev. (2006) 10.1111/j.1600-065x.2006.00457.x

[9]

Burgess-Beusse "The insulation of genes from external enhancers and silencing chromatin" Proc. Natl. Acad. Sci. USA (2002) 10.1073/pnas.162342499

[10]

Caligiuri "Human natural killer cells" Blood (2008) 10.1182/blood-2007-09-077438

[11]

Carlsten "Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications" Front. Immunol. (2015) 10.3389/fimmu.2015.00266

[12]

Chang "A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells" Cancer Res. (2013) 10.1158/0008-5472.can-12-3558

[13]

Cheng "NK cell-based immunotherapy for malignant diseases" Cell. Mol. Immunol. (2013) 10.1038/cmi.2013.10

[14]

Childs "Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens" Nat. Rev. Drug Discov. (2015) 10.1038/nrd4506

[15]

Chowdhury "Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity" Proc. Natl. Acad. Sci. USA (1998) 10.1073/pnas.95.2.669

[16]

Denman "Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells" PLoS ONE (2012) 10.1371/journal.pone.0030264

[17]

Dhar "NKG2D and its ligands in cancer" Curr. Opin. Immunol. (2018) 10.1016/j.coi.2018.02.004

[18]

Dolstra "Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients" Clin. Cancer Res. (2017) 10.1158/1078-0432.ccr-16-2981

[19]

Eagle "Promiscuity and the single receptor: NKG2D" Nat. Rev. Immunol. (2007) 10.1038/nri2144

[20]

Fesnak "Engineered T cells: the promise and challenges of cancer immunotherapy" Nat. Rev. Cancer (2016) 10.1038/nrc.2016.97

[21]

Figueroa "Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy" Int. Rev. Immunol. (2015) 10.3109/08830185.2015.1018419

[22]

Garrity "The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure" Proc. Natl. Acad. Sci. USA (2005) 10.1073/pnas.0502439102

[23]

Geller "Use of allogeneic NK cells for cancer immunotherapy" Immunotherapy (2011) 10.2217/imt.11.131

[24]

Geller "A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer" Cytotherapy (2011) 10.3109/14653249.2010.515582

[25]

Giudice "Genetic modification of human embryonic stem cells for derivation of target cells" Cell Stem Cell (2008) 10.1016/j.stem.2008.04.003

[26]

Grupp "Chimeric antigen receptor-modified T cells for acute lymphoid leukemia" N. Engl. J. Med. (2013) 10.1056/nejmoa1215134

[27]

Guillerey "Targeting natural killer cells in cancer immunotherapy" Nat. Immunol. (2016) 10.1038/ni.3518

[28]

Handgretinger "Exploitation of natural killer cells for the treatment of acute leukemia" Blood (2016) 10.1182/blood-2015-12-629055

[29]

Hassan "Mesothelin targeted cancer immunotherapy" Eur. J. Cancer (2008) 10.1016/j.ejca.2007.08.028

[30]

Hermanson "Utilizing chimeric antigen receptors to direct natural killer cell activity" Front. Immunol. (2015) 10.3389/fimmu.2015.00195

[31]

Hermanson "Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer" Stem Cells (2016) 10.1002/stem.2230

[32]

Ho "Costimulation of multiple NK cell activation receptors by NKG2D" J. Immunol. (2002) 10.4049/jimmunol.169.7.3667

[33]

Imai "Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells" Blood (2005) 10.1182/blood-2004-12-4797

[34]

Klingemann "Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells" Front. Immunol. (2016) 10.3389/fimmu.2016.00091

[35]

Knorr "Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy" Stem Cells Dev. (2013) 10.1089/scd.2012.0608

[36]

Knorr "Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy" Stem Cells Transl. Med. (2013) 10.5966/sctm.2012-0084

[37]

Koehl "Advances in clinical NK cell studies: Donor selection, manufacturing and quality control" OncoImmunology (2015) 10.1080/2162402x.2015.1115178

[38]

Koneru "IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo" OncoImmunology (2015) 10.4161/2162402x.2014.994446

[39]

Kwon "Stepwise phosphorylation of p65 promotes NF-κB activation and NK cell responses during target cell recognition" Nat. Commun. (2016) 10.1038/ncomms11686

[40]

Lanier "Up on the tightrope: natural killer cell activation and inhibition" Nat. Immunol. (2008) 10.1038/ni1581

[41]

Lanier "Co-association of CD3 zeta with a receptor (CD16) for IgG Fc on human natural killer cells" Nature (1989) 10.1038/342803a0

[42]

Liu "Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity" Leukemia (2018) 10.1038/leu.2017.226

[43]

Long "Negative signaling by inhibitory receptors: the NK cell paradigm" Immunol. Rev. (2008) 10.1111/j.1600-065x.2008.00660.x

[44]

Long "Controlling natural killer cell responses: integration of signals for activation and inhibition" Annu. Rev. Immunol. (2013) 10.1146/annurev-immunol-020711-075005

[45]

Love "ITAM-mediated signaling by the T-cell antigen receptor" Cold Spring Harb. Perspect. Biol. (2010) 10.1101/cshperspect.a002485

[46]

Maude "CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia" Blood (2015) 10.1182/blood-2014-12-580068

[47]

Miller "Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer" Blood (2005) 10.1182/blood-2004-07-2974

[48]

Moriarity "Modular assembly of transposon integratable multigene vectors using RecWay assembly" Nucleic Acids Res. (2013) 10.1093/nar/gkt115

[49]

Morvan "NK cells and cancer: you can teach innate cells new tricks" Nat. Rev. Cancer (2016) 10.1038/nrc.2015.5

[50]

Nakajima "Activating interactions in human NK cell recognition: the role of 2B4-CD48" Eur. J. Immunol. (1999) 10.1002/(sici)1521-4141(199905)29:05<1676::aid-immu1676>3.0.co;2-y

Showing 50 of 75 references

Cited By

877

Rapid CAR screening and circRNA-driven CAR-NK cells for persistent shed-resistant immunotherapy

Joo-Yoon Chung, Jisu Hong · 2026

Signal Transduction and Targeted Th...

Natural killer cell–based immunotherapy for cancer

Shoubao Ma, Jianhua Yu · 2025

The Journal of Immunology

Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy

Vlad Andrei Cianga, Ion Antohe · 2025

Frontiers in Pharmacology

Harnessing chimeric antigen receptor macrophages against solid tumors

Mengru Wang, Zhen Qin · 2025

Cancer Communications

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

Lei Peng, Giacomo Sferruzza · 2024

Cellular & Molecular Immunology

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Weishi Cheng, Kai Kang · 2024

Journal of Hematology & Oncolog...

Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions

Yan Zhong, Jingfeng Liu · 2024

Cell Death Discovery

Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors

Peng Ouyang, Lijuan Wang · 2024

Frontiers in Immunology

CAR-T therapy for ovarian cancer: Recent advances and future directions

Qianling Xin, Yizhao Chen · 2024

Biochemical Pharmacology

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Karama Makni Maalej, Maysaloun Merhi · 2023

Molecular Cancer

Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.

Aimee Merino, Joseph Maakaron · 2023

Blood Reviews

Nonviral technologies can pave the way for CAR-NK cell therapy

Tobias Bexte, Lisa Marie Reindl · 2023

Journal of Leukocyte Biology

Chimeric antigen receptor engineered natural killer cells for cancer therapy

Yalan Zhang, Weilin Zhou · 2023

Experimental Hematology & Oncol...

CAR-NK cell therapy for glioblastoma: what to do next?

Qi Xiong, Jiao Zhu · 2023

Frontiers in Oncology

A pan-cancer single-cell panorama of human natural killer cells

Fei Tang, Jinhu Li · 2023

Cell

CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy

Yun Chang, Xuechao Cai · 2023

Nature Communications

Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy

Bolong Tao, Ruoxin Du · 2023

Journal of Controlled Release

CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer

Marta Włodarczyk, Beata Pyrzynska · 2022

Cancers

The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells

Jake Moscarelli, David Zahavi · 2022

Transplantation and Cellular Therap...

CAR-NK cells for cancer immunotherapy: from bench to bedside

Leisheng Zhang, Yuan Meng · 2022

Biomarker Research

Metrics

877

Citations

75

References

Details

Published: Aug 01, 2018
Vol/Issue: 23(2)
Pages: 181-192.e5
License: View

Authors

Funding

NIH Award: R01CA203348

CIRM Award: DISC2-09615

Fate Therapeutics

Cite This Article

Ye Li, David L. Hermanson, Branden S. Moriarity, et al. (2018). Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell, 23(2), 181-192.e5. https://doi.org/10.1016/j.stem.2018.06.002

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity

You May Also Like